Stock Market Today (LIVE): AST SpaceMobile Dips 10%—Buy Now?; Honeywell Sells Barcode Biz

The article is dominated by escalating Strait of Hormuz tensions, with the U.S. seizing the Iranian vessel Touska and WTI crude rising about 6% overnight to around $89 while Brent moved back near $95. The market response is broadly risk-off, though individual stories are mixed: Compass Pathways surged about 44% on a Trump executive order for faster psychedelic approvals, while ASTS fell after losing BlueBird 7 and Rivian faced tornado-related production disruption. Corporate deal flow remains active, including QXO's $17 billion TopBuild acquisition, Lilly's up-to-$7 billion Kelonia deal, and Honeywell's $1.4 billion barcode business sale.

Analysis

The market is starting to separate “policy beta” from real execution. In biotech, the psychedelic headline is useful mainly because it re-rates the entire approval probability tree for the sector, but the first durable winner is the company with the cleanest regulatory path and the least need for incremental financing; that keeps CMPS in the lead while leaving most of the group vulnerable to a classic buy-the-rumor/sell-the-order reaction once investors realize an EO does not shortcut FDA standards.

The more actionable read is in capital structure and margin architecture. LDOS, HON, and similar asset-heavy contractors are signaling that the highest-ROIC move right now is to offload lower-margin, capex-hungry businesses and redeploy into software/mission-critical services; that should improve multiple expansion more than top-line growth alone. Expect competitors still trapped in “full-stack” operating models to lag on margin quality, especially if government spending stays sticky but not explosive.

AI hardware is moving from a single-chip story to a system-design story. The Marvell/Google angle matters less for near-term revenue and more because it tightens design-win lock-in across the 2027 upgrade cycle, while Morgan Stanley’s CPU/memory thesis implies a broader beneficiary set than the market’s current Nvidia-centric positioning. That should support a relative-value rotation into memory, foundry, and CPU-adjacent names when investors start paying for orchestration and bandwidth rather than just accelerator units.

The macro overlay is the real risk lever: a sustained Hormuz disruption is a direct tax on consumers and transport while being a near-term tailwind for energy, but the second-order effect is higher inflation volatility and lower multiples for long-duration growth. Airlines, EVs, and rate-sensitive software are the most vulnerable if crude stays elevated into the next several prints; conversely, any de-escalation headline can unwind the move quickly because positioning is likely still underhedged for a true supply shock.

Key Decisions for Investors

• Long CMPS vs short a basket of unprofitable psychedelic/early-stage biotech names for 2-6 weeks; trade the regulatory asymmetry while the sector re-rates, but reduce on any FDA process pushback.
• Buy LDOS on weakness over the next 1-3 sessions and pair it against a lower-margin defense/industrial contractor; thesis is margin expansion plus capital redeployment, with downside limited if the JV is treated as a de-risking event.
• Go long MRVL and optionally pair against NVDA over 1-3 months; the setup is a design-win/lock-in trade, with better relative upside if the market broadens AI spend from accelerators to networking, memory, and custom silicon.
• Initiate a tactical short in AAL/UAL or buy put spreads for the next 2-4 weeks while Hormuz volatility persists; oil-driven demand destruction and margin compression should hit sooner than any benefit from fare increases.
• Consider a barbell long QXO / BLD into the merger window, but size modestly; the risk/reward is favorable if synergies get believed, though deal execution and financing sentiment are the main failure points.